A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: Effect on metastatic bone pain

American Journal of Therapeutics

Volumn 18, Issue 5, 2011, Pages 340-342

  Heras, Panagiotis ^a,b,c   Hatzopoulos, Antonios ^a   Heras, Vasilios ^c   Kritikos, Nikolaos ^c   Karagiannis, Stefanos ^b,c   Kritikos, Konstantinos ^b,c  

^a General Hospital of Nafplio   (Greece)

^b General Hospital of Cos   (Greece)

^c Hellenic Medical Society for the Study of Psychosomatic Problems   (Greece)

Author keywords

bone metastases; bone pain; breast cancer; ibandronate; lung cancer; pamindronate

Indexed keywords

CALCIUM; CREATININE; IBANDRONIC ACID; PAMIDRONIC ACID;

ADULT; ARTICLE; BONE ATROPHY; BONE METASTASIS; BONE PAIN; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; LINEAR ANALOG SCALE ASSESSMENT; LUNG CANCER; MALE; METASTATIC BONE PAIN; PAIN ASSESSMENT; PATIENT MOBILITY; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; TREATMENT OUTCOME;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PAIN; QUALITY OF LIFE;

EID: 80052727149     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181e70c38     Document Type: Article

References (16)

1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165-176. (Pubitemid 32452017)
2. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042-4057. (Pubitemid 46606220)
3. Coleman RE. Bisphosphonate: clinical experience. Oncologist. 2004;9(Suppl 4):14-27.
4. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003;14:1399-1405. (Pubitemid 37185286)
5. Body JJ, Diel IJ, Lichinitzer MR, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer. 2004;90:1133-1137. (Pubitemid 38496803)
6. Diel IJ, Body JJ, Lichinitzer MR, et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer. 2004;40:1704-1712. (Pubitemid 38902906)
7. Body JJ, Diel IJ, Bell R, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain. 2004;111: 306-312. (Pubitemid 39201152)
8. Heidenreich A, Elert A, Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis. 2002;5:231-235.
9. Ohlmann C, Heidenreich A. Efficacy of ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer. Support Care Cancer. 2003;11:396 (A-38).
10. Heidenreich A, Ohlmann C, Olbert P, et al. High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer. 2003;1(Suppl 5):S270.
11. Mancini I, Dumon JC, Body JJ. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol. 2004;22:3587-3592. (Pubitemid 41103666)
12. Clarke NW, Holbrook IB, McClure J, et al. Osteoclast inhibition by pamindronate in metastatic prostate cancer: a preliminary study. Br J Cancer. 1991;63:420-423.
13. Lipton A, Glover D, Harvey H, et al. Pamindronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann Oncol. 1994;5(Suppl 7):S31-S35.
14. Small EJ, Smith MR, Seaman JJ, et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamindronate disodium for the palliation of bone pain in men with metastatic prostate cancer. Clin Oncol. 2003;21:4277-4284. (Pubitemid 46621802)
15. Purohit OP, Anthony C, Radstone CR, et al. High-dose intravenous pamindronate for metastatic bone pain. Br J Cancer. 1994;70:554-558. (Pubitemid 24268564)
16. Coleman RE, Purohit OP, Vinholes JJ, et al. High dose pamindronate: clinical and biochemical effects in metastatic bone disease. Cancer. 1997;80(Suppl 8):1686-1690. (Pubitemid 27444042)